174 related articles for article (PubMed ID: 8116130)
1. Intravesical therapy in superficial bladder cancer.
Witjes JA; Mulders PF; Debruyne FM
Urology; 1994 Feb; 43(2 Suppl):2-5; discussion 6. PubMed ID: 8116130
[TBL] [Abstract][Full Text] [Related]
2. Oral or intravesical bacillus Calmette-Guerin immunoprophylaxis in bladder carcinoma.
D'Ancona CA; Netto Júnior NR; Claro JA; Ikari O
J Urol; 1991 Mar; 145(3):498-501. PubMed ID: 1997698
[TBL] [Abstract][Full Text] [Related]
3. Use of maintenance intravesical bacillus Calmette-Guérin (BCG), with or without intradermal BCG, in patients with recurrent superficial bladder cancer. Long-term follow-up of a randomized phase 2 study.
Witjes JA; Fransen MP; van der Meijden AP; Doesburg WH; Debruyne FM
Urol Int; 1993; 51(2):67-72. PubMed ID: 8351757
[TBL] [Abstract][Full Text] [Related]
4. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
[TBL] [Abstract][Full Text] [Related]
5. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
6. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
7. Intravesical bacillus Calmette-Guerin for superficial bladder cancer: experience with Danish 1331 strain.
Kamat MR; Kulkarni JN; Tongaonkar HB; Dalal AV
J Urol; 1994 Nov; 152(5 Pt 1):1424-8. PubMed ID: 7933175
[TBL] [Abstract][Full Text] [Related]
8. Intravesical versus intravesical plus intradermal bacillus Calmette-Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors.
Lüftenegger W; Ackermann DK; Futterlieb A; Kraft R; Minder CE; Nadelhaft P; Studer UE
J Urol; 1996 Feb; 155(2):483-7. PubMed ID: 8558641
[TBL] [Abstract][Full Text] [Related]
9. Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer.
Melekos MD; Chionis HS; Paranychianakis GS; Dauaher HH
Cancer; 1993 Sep; 72(5):1749-55. PubMed ID: 8348504
[TBL] [Abstract][Full Text] [Related]
10. A randomized multicenter trial of adjuvant therapy in superficial bladder cancer: transurethral resection only versus transurethral resection plus mitomycin C versus transurethral resection plus bacillus Calmette-Guerin. Participating Clinics.
Krege S; Giani G; Meyer R; Otto T; Rübben H
J Urol; 1996 Sep; 156(3):962-6. PubMed ID: 8709374
[TBL] [Abstract][Full Text] [Related]
11. Do prognostic parameters of remission versus relapse after Bacillus Calmette-Guérin (BCG) immunotherapy exist?. analysis of a quarter century of literature.
Saint F; Salomon L; Quintela R; Cicco A; Hoznek A; Abbou CC; Chopin DK
Eur Urol; 2003 Apr; 43(4):351-60; discussion 360-1. PubMed ID: 12667715
[TBL] [Abstract][Full Text] [Related]
12. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.
Pham HT; Soloway MS
Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909
[TBL] [Abstract][Full Text] [Related]
13. Use of intravesical bacillus Calmette-Guérin in the treatment of superficial transitional cell carcinoma of the bladder: an overview.
Witjes JA; vd Meijden AP; Debruyne FM
Urol Int; 1990; 45(3):129-36. PubMed ID: 2190404
[TBL] [Abstract][Full Text] [Related]
14. Intravesical bacillus Calmette-Guérin therapy for T1 superficial bladder cancer.
Demkow T; Alter A; Wiechno P
Urol Int; 2008; 80(1):74-9. PubMed ID: 18204238
[TBL] [Abstract][Full Text] [Related]
15. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
[TBL] [Abstract][Full Text] [Related]
16. The response of patients with superficial bladder cancer to a second course of intravesical bacillus Calmette-Guerin.
Bretton PR; Herr HW; Kimmel M; Whitmore WF; Laudone V; Oettgen HF; Fair WR
J Urol; 1990 Apr; 143(4):710-2; discussion 712-3. PubMed ID: 2313796
[TBL] [Abstract][Full Text] [Related]
17. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
[TBL] [Abstract][Full Text] [Related]
18. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
[TBL] [Abstract][Full Text] [Related]
19. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
[TBL] [Abstract][Full Text] [Related]
20. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
